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1. Summary
Glycoconjugate-based vaccines have proved to be effective at producing long-
lasting protection against numerous pathogens. Here, we describe the application
of bacterial protein glycan coupling technology (PGCT) to generate a novel recom-
binant glycoconjugate vaccine. We demonstrate the conjugation of the Francisella
tularensis O-antigen to the Pseudomonas aeruginosa carrier protein exotoxin A
using the Campylobacter jejuni PglB oligosaccharyltransferase. The resultant recom-
binant F. tularensis glycoconjugate vaccine is expressed in Escherichia coli where
yields of 3 mg l21 of culture were routinely produced in a single-step purification
process. Vaccination of BALB/c mice with the purified glycoconjugate boosted
IgG levels and significantly increased the time to death upon subsequent challenge
with F. tularensis subsp. holarctica. PGCT allows different polysaccharide and
protein combinations to be produced recombinantly and could be easily applicable
for the production of diverse glycoconjugate vaccines.
2. Introduction
Vaccines more than any other medical intervention measure have improved the
lives ofmankind.When selecting a vaccine, there are a number of choices. Live atte-
nuated vaccines carry the advantage of exposing the host to an array of
immunogenic epitopes, often leading to generation of humoral and cellular immu-
nity; however, they also carry the risk of reversion to full virulence and they cannot
be administered to immunosuppressed individuals. Killed vaccines are cheaper to
store than live attenuated vaccines; however, only humoral immunity is induced
resulting in the need to vaccinate individuals multiple times. A defining character-
istic of a successful vaccine is the ability to evoke long-lasting protective immunity
with minimal side effects. One strategy that has been particularly successful in
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achieving this goal is the use of glycoconjugate vaccines, which
combine an immunogenic protein coupled to a glycan to induce
both humoral and cellular immune responses. Additionally,
subunit vaccines can be administered to immunosuppressed
individuals. Examples of currently licensed human glycoconju-
gate vaccines include those against Haemophilus influenzae,
Neisseriameningitidis and Streptococcus pneumoniae, inwhich bac-
terial polysaccharides are chemically bound to carrier proteins
[1,2]. In the case of the H. influenza type B (Hib) vaccine, the
carrier protein iCRM197 is a non-toxic version of diphtheria
toxin isolated from Corynebacterium diphtheriae [3]. This same
carrier protein is used in the Prevnar 13-valent capsule-based
glycoconjugate vaccine that can be administered to infants as
well as adults to protect against invasive disease caused by
S. pneumoniae [4]. Although these glycoconjugate vaccines are
extremely effective, their production using current technology
requires both the purification of polysaccharide glycan from
the native pathogen and the chemical coupling of the sugar to
a suitable protein carrier, which can lead to impure products
and batch variation between glycoconjugate preparations.
In addition, the multistep process is expensive, time consuming
and does not facilitate the construction and testing of diverse
protein/glycan combinations. Here, we describe the develop-
ment and optimization of a recombinant approach to the
production of glycoconjugate vaccines that circumvents these
problems toprovide an inexhaustible supplyofpurifiedproduct.
In recent years, general glycosylation systems have
been identified in several bacterial species. For example, in
Campylobacter jejuni a 16-kb gene locus that encodes a general
N-linked glycosylation system has been characterized and
found to modify over 50 proteins with a heptasaccharide
glycan [5,6]. Remarkably, the general glycosylation locus func-
tions in Escherichia coli and can be used to couple some glycans
to a variety of proteins including non-Campylobacter proteins,
as long as an appropriate acceptor sequon D/E-X-N-Y-S/T
(where Y and X are any amino acid except P) is present on the
acceptor protein [7,8]. The oligosaccharyltransferase (CjPglB) in
the locus can transfer alternative glycans from other organisms,
implying a relaxed specificity for the enzyme [9]. This rela-
xed reducing end sugar specificity has been demonstrated for
N-acetylgalactosamine from the O-antigen of E. coli O157,
N-aceytlglucosamine from the O-antigen of E. coli O7, O16
andO9a,N-acetylfucosamine from theO-antigen ofPseudomonas
aeruginosa O11 and bacillosamine (2,4-diacetamido-2,4,6-
trideoxyglucose) from the native C. jejuni heptasaccharide
[9–11]. These developments have demonstrated the potential
for producing novel combinations of glycoconjugates and have
been termed bacterial protein glycan coupling technology
(PGCT; figure 1) [12,13]. PGCT provides an efficient cloning
method of glycoconjugate production in thewidely used bacter-
ium E. coli. Recent examples include the transfer of the Yersinia
enterocolitica 09 O-antigen to the C. jejuni acceptor protein
AcrA [14] and the Shigella dysenteriaeO-antigen to a P. aeruginosa
exotoxin A (ExoA) variant [15]. However, these novel protein/
glycan combinations have not been reported to be protective
and the potential for PGCT in glycoconjugate vaccine
production has yet to be realized.
Francisella tularensis is a Gram-negative, facultative coccoba-
cillus. It is the causative agent of tularaemia and is considered
oneof themost infectious bacteria known toman, yet there is cur-
rently no licensed vaccine available [16]. A single inhaled bacillus
is capableofproducing infection in40–50%of individuals,witha
mortality rate of up to 30 per cent [17]. There are two strains
pathogenic to humans, F. tularensis subspecies tularensis or type
A,which is associatedwith illness inNorthAmerica, andF. tular-
ensis subspecies holarctica, also known as type B, which is less
virulent but has a higher global burden and is associated with
infections in Europe [18]. F. tularensis is also classified as a class
Abioterrorismagentbasedon its low infectiousdose, high fatality
rateandeaseof aerosoldistribution,makingvaccinedevelopment
a high priority for national security interests [19]. Themost prom-
ising candidate todatehasbeena livevaccine strain (LVS)derived
from subspecies holarctica that has been tested in human
volunteers [20–22]. However, this vaccine is still capable of caus-
ing disease in murine infection models [23] and provides only
partial protection against the most virulent type A strains [24].
Therefore, a vaccine capable of conferring protection against
both types A and B of F. tularensis remains an imperative.
The protective efficiency of a glycoconjugate vaccine
relies on the ability of a glycan to induce a strong immune
response, and it has previously been shown that vaccination
with purified lipopolysaccharide (LPS) from F. tularensis LVS
OM
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Figure 1. Principles of protein glycan coupling technology in E. coli. An E. coli cell is transformed with three plasmids to generate the cloned glycoconjugate protein
(GP). The plasmids carry the oligosaccharyltransferase PglB, the biosynthetic polysaccharide locus and the carrier protein. The polysaccharide is synthesized on an
undecaprenol pyrophosphate lipid anchor (blue/black circle) within the cytoplasm; this is transferred to the periplasmic compartment where PglB recognizes the lipid
linked reducing end sugar and transfers the polysaccharide en bloc onto an acceptor sequon (D/E-X-N-X-S/T) on the carrier protein to produce the GP. IM, inner
membrane; OM, outer membrane.
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afforded protection against subsequent F. tularensis LVS chal-
lenge in the murine tularaemia infection model [25]. The
prevalent immune response was humoral [26], although
recently F. tularensis LPS has been found to cause prolifer-
ation of a rare subset of B-1a lymphocytes cells in the
absence of T-cell help or TLR4 stimulation in mice, indicating
that the immune response to this antigen cannot be classified
either as innate or adaptive [27]. The polysaccharide moiety
alone is insufficient for long-lasting immunological memory
cell proliferation [28], but several studies have confirmed
that this organism’s O-antigen repeat unit is an important
immunogen [25,26,29,30] and it would be predicted that
coupling the O-antigen to an immunogenic protein carrier
would provide a longer lasting T-cell dependent immune
response. However, the chemical conjugation method used
and the handling of highly infectious agents makes the puri-
fication and production of these vaccines extremely difficult.
In this study, we clone and express the F. tularensis
O-antigen coding region in E. coli and transfer it to the accep-
tor protein ExoA from P. aeruginosa using PGCT. We show for
the first time that the Francisella tularensis O-antigen can be
transferred by PGCT, and have produced a novel candidate
vaccine in the murine F. tularensis infection model. The puri-
fied recombinant glycoconjugate vaccine was easily purified
in high yields and was capable of providing significant pro-
tection against subsequent challenge with a virulent wild-
type strain of F. tularensis subsp. holarctica, demonstrating a
considerable improvement over the LPS unconjugated vac-
cine. This demonstrates that PGCT can be used to generate
efficacious glycoconjugate vaccines, and the technique
could be adapted to a variety of other pathogens.
3. Material and methods
3.1. Bacterial strains and plasmids
Escherichia coli strains were grown in Luria-Bertani (LB) broth at
378C, with shaking. Antibiotics were used at the following con-
centrations: tetracycline 20 mg ml21, ampicillin 100 mg ml21,
spectinomycin 80 mg ml21 and chloramphenicol 30 mg ml21.
The host strain for initial cloning experiments was E. coli XL-1,
subsequent strains used for glycoconjugate production were
E. coli DH5a and CLM24 (see the electronic supplementary
material, table S1). For efficacy studies, mice were challenged
with F. tularensis subsp. holarctica strain HN63. F. tularensis
HN63 was cultured on blood cysteine glucose agar (BCGA)
plates (supplemented with 10 ml of 10% (w/v) histidine
per litre) at 378C for 18 h. The bacteria were suspended in
phosphate-buffered saline (PBS) to an OD550 nm of 0.1, equival-
ent to 1  109 colony forming units (CFU) per ml. Dilutions
were made in PBS and mice were infected with 100 CFU via
the intra-peritoneal (IP) route.
3.2. Cloning, sequencing and expression of the
Francisella tularensis O-antigen coding region
DNA was prepared from the F. tularensis subsp. tularensis
strain SchuS4 by phenol extraction as described by Karlsson
et al. [31]. The O-antigen coding region was amplified using
the primers FTfragment2rev (50-GGATCATTAATAGC
TAAATGTAGTGCTG-30) and Oant1ftfwd (50-TTTTGAATT
CTACAGGCTGTCAATGGAGAATG-30) using the following
cycling conditions: 948C, 15 s, 558C, 15 s, 688C, 20 min; 35
cycles using Accuprime Taq Hifi (Invitrogen, UK). This was
cloned into the TA cloning vector pGEM-T Easy to generate
the vector pGAB1. The plasmid pGAB1 was digested with
EcoRI in order to subclone the insert into the vector pLAFR
to generate the construct pGAB2.
3.3. Immunofluorescence imaging of Escherichia
coli cells carrying Francisella tularensis
O-antigen-coding region
Approximately 1  109 CFU of E. coli DH5a cells were fixed on
separate glass cover slips by air-drying and washed in PBS.
Cover slips were then incubated in 5% v/v fetal calf serum
(FCS) in PBS for 2 h. After three 2 min washes in PBS, cover
slips were incubated with IgG2a mouse monoclonal antibody
(mAb) FB11 (1 ml ml21 in 5% (v/v) FCS/PBS) for 1 h at 378C
and, following three washes in PBS, bacteria were air dried on
a glass coverslip and probed with Alexa Fluor 488 goat anti-
mouse IgG (whole molecule, Invitrogen Life Technologies
Corp.). Cover slips were mounted on a glass slide using
Vectashield mounting medium containing the DNA-specific
counter stain 40, 6-diamidino-2-phenylindole (DAPI). The level
of fluorescence for each isolate was observed under fluorescent
microscopy using an Olympus FluoView laser scanning
microscope (Olympus Imaging and Audio Ltd).
3.4. Immunoblot analysis
To verify the transfer and presence of the F. tularensisO-antigen,
samples were analysed by western blotting. Escherichia coli cells
were grown overnight in 10 ml LB broth and subsequently
diluted to an OD600 nm of 1.0. Cells were isolated by centrifu-
gation at 12 100g for 10 min, the supernatant was removed
and cells were resuspended in 100 ml Laemmli buffer. Cells
were lysed by boiling for 10 min before analysis by western
blotting or silver staining. Mouse anti-F. tularensis O-antigen
monoclonal antibody FB011 (AbCam, UK) was used at a
dilution of 1 : 1000, and rabbit anti-HIS monoclonal antibody
was used to detect ExoA at a dilution of 1 : 10 000. Secon-
dary antibodies used were goat anti-mouse IRDye680 and
IRDye800 conjugates used at 1 : 5000 dilutions. Signal detection
wasundertakenusing theOdysseyLI-CORdetectionsystem(LI-
COR Biosciences GmbH).
3.5. Determination of glycosylation sequon occupancy
within exotoxin A
To establish if the asparagine residues at amino acid positions
262 and 404 within ExoA were both capable of being glycosy-
lated with the F. tularensis O-antigen, these residues were
altered to glutamine (260DNNNS264 altered to 260DNQNS264
and 402DQNRT406 altered to 402DQQRT406) using an Invitrogen
QuikChange XL kit according to manufacturer’s instructions
(Invitrogen Life Technologies Corp.).
The primers a826c_t828g 50-gacctggacatcaaggataatcaga-30
and a826c_t828g_ant 50-atgaccgtgggagtagaattctgatt-30 were
used to mutate the 260DNNNS264 to yield pGVXN150260
DNQNS264 and the primers a1252c_t1254g 50-tgccccgtcgc
caaagatcaacagagaactaaaggggaatg-30 and a1252c_t1254g_a
50-cattcccctttagttctctgttgatctttggcgacggggca-30 to mutate
rsob.royalsocietypublishing.org
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402DQNRT406 to yield pGVXN150402DQQRT406. The construct
carrying the glutamine modification at amino acid position
262was subjected to a second round of QuikChange to generate
pGVXN150260DNQNS264/402DQQRT406 to act as a negative gly-
cosylation control. All modified constructs were generate using
the following cycling conditions: one cycle of 958C per 1 min,
followed by 18 cycles of 958C per 50 s, 608C per 50 s, 688C per
7 min 30 s and a final step of 688C per 1 min.
Escherichia coli CLM24 carrying the vectors pGAB2,
pGVXN114 and pGVXN150 or the glycosylation sequon
modified pGVXN150260DNQNS264/pGVXN150402DQQRT406/
pGVXN150260DNQNS264/402DQQRT406 was grown for 16 h in
10 ml LB broth at 378C, with shaking. 0.5 ml of this culture was
used to inoculate 9.5 ml of LB broth and further incubated with
shaking at 378C until an OD600 reading of 0.4–0.6 was reached.
At this point, L-arabinose was added to a final concentration of
0.2 per cent and isopropyl b-D-1-thiogalactopyranoside (IPTG)
to a final concentration of 1 mM to induce expression of exoA
and CjpglB, respectively. After 4 h of induction, cells were pel-
leted by centrifugation at 12 100g for 10 min. Cells were
resuspended in 1 ml 50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole, pH 8.0 supplemented with 0.1 per cent Tween,
1 mg ml21 lysozyme and 1 ml ml21 Benzonase nuclease (Nova-
gen) and lysed using a Bioruptor sonicator (Diagenode, UK) on
high settings on a cycle consisting of 30 s on and 30 s off for
15 min. The resulting lysate was centrifuged at 12 100g for
10 min and the supernatant transferred to a fresh 1.5 ml tube
before 50 ml ofNi-NTAagarose (QIAGEN)was added. The agar-
ose lysate mixture was incubated at 48C for 1 h before being
loaded into microcentrifuge spin cups (Thermo Scientific, Pierce
Spin Cups, Thermo Scientific Inc.) and centrifuged at 1670g for
2 min. His-tagged ExoA was purified according to manufac-
turer’s instructions (QIA expressionist, QIAGEN); protein was
eluted in 50 ml of elution buffer containing 250 mM imidazole.
Purified protein was tested by western blotting as
described above.
3.6. Production and purification of glycoconjugate
vaccine
Escherichia coli CLM24 carrying the vectors pGAB2, pGVXN114
and pGVXN150 was grown as described above with some
modifications. Escherichia coli cells were grown for 16 h in
200 ml LB broth at 378C, with shaking. This was used to inocu-
late 1.8 l of LB broth and further incubated with shaking at
378C until an OD600 reading of 0.4–0.6 was reached. At this
point L-arabinose was added to a final concentration of 0.2
per cent and IPTG to a final concentration of 1 mM to induce
expression of exoA and CjpglB, respectively; after another 5 h
of incubation, 0.2 per cent L-arabinose was added again and
the culture left to incubate overnight.
Cells were harvested by centrifugation at 5300g for
30 min, and pelleted cells were incubated at room tempera-
ture for 30 min in a lysis solution composed of 10
BugBuster protein extraction reagent (Novagen) diluted to
1 in 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole,
pH 8.0 supplemented with 0.1 per cent Tween, 1 mg ml21
lysozyme and 1 ml ml21 Benzonase nuclease (Novagen).
Cell debris was removed by centrifugation at 7840g for
30 min, the supernatant was collected and 1 ml Ni-NTA
agarose (QIAGEN) was added to the supernatant. The
slurry-lysate was incubated for 1 h at 48C with shaking
then loaded into 10 ml polypropylene columns (Thermo
Scientific). His-tagged ExoA was purified by the addition of
an elution buffer according to manufacturer’s instructions
(QIA expressionist, QIAGEN) containing 250 mM imidazole
with the addition of 20 per cent glycerol and 5 per cent glu-
cose. Protein yields were estimated using a bicinchonic acid
assay kit according to manufacturer’s instructions (Pierce
Biotechnology BCA Protein Assay Kit, USA).
For large-scale protein purification, material was isolated
using GE Healthcare HIS trap columns and an AKTA purifier
with an imidazole gradient of 30 to 500 mM. The collected frac-
tion containing ExoA glycosylated with F. tularensis O-antigen
was further purified using a resource Q anionic exchange
column (GE Healthcare) with a NaCl gradient from 0 to
500 mM in 20 mM Tris HCl pH 8.0. This generated a typical
yield of 2–3 mgml21 of glycoconjugate per 2 l of E. coli culture.
The same techniques were used for the generation of the
‘sham’ C. jejuni heptasaccharide ExoA glycoconjugate. The
plasmid coding for this heptasaccharide was pACYCpgl
carrying the entire Cjpgl cluster from C. jejuni 81116 [5].
3.7. BALB/c mouse challenge studies
Female Balb/c mice were obtained from Charles River Lab-
oratories (Kent, UK) at six to eight weeks of age. The pilot
study was done in groups of 10 mice immunized with
either 0.5 mg F. tularensis LPS, 0.5 mg F. tularensis glycoconju-
gate, 0.5 mg F. tularensis glycoconjugate þ Sigma Adjuvant
System (SAS), 0.5 mg ‘sham’ glycoconjugate þ SAS, 0.5 mg
‘sham’ glycoconjugate or SAS only. In addition, one group
of mice were left untreated as challenge efficacy controls.
The amount of SAS used was a 1 : 1 ratio (for example,
50 ml bioconjugate in PBS þ 50 ml SAS).
The SAS solutionwasmade by re-suspending 1 vial contain-
ing 0.5 mg monophosphoryl lipid A (detoxified endotoxin)
from Salmonella minnesota and 0.5 mg synthetic trehalose
dicorynomycolate in 2 per cent oil (squalene)–Tween 80–water
in 1 ml PBS.
Immunizations occurred on days 0, 14 and 28 via the
IP route. Mice were challenged 35 days after the last immuniz-
ation with 100 CFU of F. tularensis strain HN63 by the IP route,
delivered in 0.1 ml. Subsequent experiments used the same
vaccination schedules except for increasing the number of
mice per group to 15 and increasing doses to 10 mg of material
per animal per immunization. Four weeks following final vac-
cination, five mice from each group were tail bled to obtain
sera for antibody analysis. On day 3 post-infection, the same
five mice from each group were culled, and spleens were har-
vested and analysed for bacterial load and cytokine response.
For organ load determination, spleen samples were homogen-
ized in 2 ml of PBS through 40 mm cell sieves (BD Biosciences).
Cell suspension of 100 ml aliquots were plated onto BCGA
plates for the enumeration of bacteria. All work was per-
formed under the regulations of the UK Home Office
Scientific Procedures Act (1986).
3.8. Immunology
Francisella tularensis LPS-specific IgM and total IgG levels
were determined in serum samples by ELISA as previously
described [32]. Spleen supernatants were assessed using
mouse inflammatory cytometric bead array kit for interleukin
(IL)-10, IL-12p70, interferon-g, IL-6, tumour necrosis factor-a,
rsob.royalsocietypublishing.org
Open
Biol3:130002
4
and monocyte chemoattractant protein-1 in accordance with
manufacturer’s instructions (CBA; BD biosciences). Cytokine
concentrations were measured via quantification of PE fluor-
escence of samples in reference to a standard curve using a
BD FACS Canto flow cytometer (BD biosciences).
3.9. Statistical analysis
All figures were generated using the program GRAPHPAD PRISM
v. 5.0. Statistical analyses were performed using the program
PASW (SPSS release 18.0). Survival data were analysed by
pair-wise log rank test stratified by experiment. Cytokine and
bacterial load data were transformed to the logarithm 10
and analysed using a univariate general linear model, using
Bonferroni’s post-tests to further clarify significant differences.
4. Results
4.1. Expression of the Francisella tularensis SchuS4
O-antigen in Escherichia coli DH5a cells
The bacterial strains and vectors used in this study are sum-
marized in the electronic supplementary material, table S1.
The 20 kb F. tularensis SchuS4 O-antigen coding region was
PCR amplified and cloned into pGEM-T Easy to generate
the plasmid pGAB1. To confirm O-antigen expression and
transport to the outer cell surface of E. coli, pGAB1 was trans-
formed into DH5a cells and probed by immunofluorescence
using mAb FB11, specific to the F. tularensis O-antigen.
Figure 2c demonstrates the expression of the O-antigen on
the surface of E. coli DH5a cells, which is absent in the
vector-alone control (figure 2d ). The presence of E. coli
DH5a cells was confirmed by staining the respective samples
with DAPI to visualize nucleic acid (figure 2a,b).
4.2. Oligosaccharyltransferase can transfer Francisella
tularensis O-antigen to the acceptor protein
exotoxin A
In order to generate a strong IgG response and lasting immu-
nity, a highly immunogenic protein is required as a carrier for
the F. tularensis O-antigen. The selected carrier protein was an
inactivated form of the ExoA variant (L552V, DE553) [15]. The
protein was modified to carry two N-glycosylation sequons
(N262 and N404), a C-terminal His tag and a signal peptide
sequence from the E. coli protein DsbA fused to the N-terminal
to localize ExoA to the periplasm of the E. coli host cell [15].
The F. tularensis O-antigen coding region was subcloned from
pGAB1 into the unique EcoRI site of the low copy vector
pLAFR1 [33] to yield the vector pGAB2. The plasmids
pGAB2, pGVXN114 and pGVXN150 containing the O-antigen,
CjPglB and ExoA, respectively, were transformed into E. coli
strain CLM24 that has a deletion in the waaL gene rendering
the E. coli host strain ligase negative and unable to transfer
UndPP-linked glycan to lipid A, therefore generating a lipid-
linked substrate specific for CjPglB. As negative glycosylation
controls, CLM24 cells were transformed with pGVXN150
alone and also with the combination of pGAB2, pGVXN150
and pGVXN115, the latter coding for a version of CjPglB with
point mutations within a domain involved in acceptor sequon
recognition from 457WWDYGY462 to 457WAAYGY462 [5]. Fol-
lowing overnight induction of CjpglB and exoA expression
with 1 mM IPTG and 0.2% L-arabinose (w/v), respectively,
cells were lysed and His-tagged ExoA purified using a nickel
column. Four elution fractions from each sample were separa-
ted by SDS PAGE and tested by immunoblotting using the
mAb FB011 specific for F. tularensis LPS. A band matching
the expected size of ExoA and an O-antigen-like pattern could
only be purified when a functional CjPglB was present
(figure 3, lanes 2 and 2b). In the absence of a functional
CjPglB there was no cross-reaction with mAb FB11 (figure 3,
lanes 1 and 3). Typical yields were 3 mg ml21 of protein after
the one step purification procedure. The His-tagged ExoA
F. tularensis O-antigen conjugate (now termed glycoconjugate)
was purified using Ni-NTA agarose (QIAGEN) and digested
with Proteinase K. The disappearance of the O-antigen ladder
after Proteinase K treatment but not in the untreated sample
confirmed that the O-antigen was anchored to ExoA (see the
electronic supplementary material, figure S1).
In order to test if F. tularensisOantigenwas capable of glyco-
sylating ExoA at both glycosylation sequons we generated site-
directed mutants of the asparagine residues found at amino
acid positions 262 and 404 and modified them to glutamines.
A version of ExoAwith both asparagines altered to glutamines
DAPI(a) (c)
(d)(b) DAPI
pGAB1 pGAB1
anti-LPS
anti-LPS
pGEM-TEasy pGEM-TEasy
Figure 2. Francisella tularensis SchuS4 O-antigen is expressed in E. coli DH5a cells. E. coli cells carrying the F. tularensis vector pGAB1 (containing O-antigen coding
region) and empty pGEM-T Easy vector, respectively, stained with DAPI to visualize nucleic acid in blue (a,b) and probed with mAb FB11 and Alexa Fluor 488
conjugated secondary antibody (c,d ). Images are shown at 100 magnification.
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was also generated as a negative control. The results from a
4 h induction of protein expression and small-scale protein
purification demonstrated that both the 260DNNNS264 and
402DQNRT406 sequons can be occupied by the polysaccharide
(see the electronic supplementary material, figure S2).
4.3. Vaccination with the glycoconjugate provides
significant protection against Francisella tularensis
subsp. holarctica infection in mice
In a pilot study we compared LPS alone against the glycocon-
jugate vaccine and monitored antibody levels and murine
survival. In order to demonstrate the specificity of the glycocon-
jugate, we used controls that included mice with SAS adjuvant
alone, unvaccinated naive mice and mice that were vaccinated
with a ‘sham’ glycoconjugate control (C. jejuni heptasaccharide
conjugated to ExoA). In this pilot study, the only vaccina-
ted groups of mice that demonstrated increased survival
compared with the appropriate controls were the 0.5 mg test
glycoconjugate þ SAS (p, 0.05) and 0.5 mg LPS (p, 0.001),
determined by log rank test (see the electronic supplementary
material, figure S3). These candidates were selected for further
assessment at higher doses and a further group consisting
of LPSþ SAS was also added to determine if this combina-
tion matched the glycoconjugate þ SAS group. Protection
was compared between mice immunized with either 10 mg
glycoconjugate þ SAS, 10 mg LPS or 10 mg LPSþ SAS. All
three vaccines were protective when compared with the unvac-
cinated mice (p, 0.001), and the SAS adjuvant alone did not
elicit any protection (p. 0.05; figure 4). This experiment also
indicated that LPS þ SAS did not elicit the same level of protec-
tion as the glycoconjugate þ SAS combination (p, 0.05) and
thereafter LPS þ SAS was deemed unnecessary for testing.
The study was repeated in order to provide further bacterial
organ load and immunological response data.
4.4. Mice vaccinated with test glycoconjugate and
challenged with Francisella tularensis subsp.
holarctica have lower bacterial loads and pro-
inflammatory cytokines 3 days post-challenge
Three days post-challenge, five mice per group were sacrificed
and bacterial loads in the spleens and the inflammatory
EPAFT
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Figure 3. F. tularensis O-antigen is conjugated to ExoA by CjPglB in E. coli CLM24 cells. Two-colour immunoblots performed on His-tag purified ExoA using mouse
mAb FB11 (green) and rabbit anti-6 His-tag antibody (red). Lane 1, E. coli CLM24 carrying pGAB2, pGVXN150, pGVXN115 (non-functional CjPglB control); lane 2,
pGAB2, pGVXN150, pGVXN114 (functional CjPglB); lane 3, pGVXN150 only; panel 2b, close up view of His-tagged purified ExoA attached to various chain lengths of
F. tularensis O-antigen. M ¼ marker IRDye 680/800 protein marker. pGVXN150 contains ExoA, pGAB2 contains F. tularensis O-antigen, pGVXN114 and pGVXN115
carry a functional and non-functional CjPglB respectively.
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Figure 4. Vaccination with test glycoconjugate increases host survival compared
with LPS and controls. Balb/C mice were vaccinated with three doses, two weeks
apart, with glycoconjugate vaccine or relevant controls (n ¼ 10 per group). Mice
were challenged five weeks following final vaccination with 100 CFU of F. tular-
ensis strain HN63 via the IP route. Mice were vaccinated with 10 mg of test
glycoconjugate þ SAS, LPS þ SAS or 10 mg LPS and the data were analysed
by stratified log rank test. Both LPS, LPS þ SAS and test glycoconjugate provided
improved protection when compared with the relevant unvaccinated controls ( p
, 0.001) and the SAS alone provided no survival benefit ( p. 0.05). The test
glycoconjugate provided significantly better protection than the LPS alone or
LPS þ SAS vaccine ( p, 0.001 and p ¼ 0.025, respectively).
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Figure 5. Mice vaccinated with test glycoconjugate show a reduced bacterial
load in spleens compared with LPS and controls. Unvaccinated, SAS vaccinated,
10 mg LPS, or 10 mg test glycoconjugate þ SAS vaccinated mice were chal-
lenged with 100 CFU of F. tularensis strain HN63 via the IP route. Spleens were
removed 3 days post-infection from each group (n ¼ 5) and assessed for bac-
terial CFUs. Logarithm data were analysed using a general linear model and
Bonferroni’s post-tests. There was no difference in bacterial load between
SAS vaccinated and unvaccinated mice ( p. 0.05) but the 10 mg LPS or
10 mg test glycoconjugate vaccinations had significantly decreased bacterial
load when compared with relevant controls ( p, 0.001). Mice vaccinated
with the test glycoconjugate þ SAS had significantly reduced bacterial num-
bers in the spleen compared with LPS ( p, 0.05).
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responses were evaluated (figure 5). Figure 5 shows the bac-
terial loads from the spleens of mice vaccinated with 10 mg
of each candidate. In both experiments, mice that were immu-
nized with the glycoconjugate þ SAS or LPS had significantly
decreased bacterial loads in spleens ( p, 0.01) when com-
pared with the SAS and unvaccinated controls. In addition,
when mice vaccinated with glycoconjugate þ SAS were
compared with those vaccinated with LPS alone, significantly
less bacteria were enumerated in spleens ( p, 0.05). Inflam-
matory cytokine profiles between the different vaccine
groups were also analysed (see the electronic supplementary
material, figure S4). Mice vaccinated with glycoconjugate þ
SAS and LPS alone had reduced levels of inflammatory cyto-
kines when compared with the SAS and unvaccinated
controls ( p, 0.05), corresponding with the decreased bac-
terial loads. There was no significant difference between
cytokine profiles for both experiments ( p. 0.05).
4.5. Vaccination with the Francisella tularensis
glycoconjugate induces a greater IgG immune
response
The levels of LPS-specific IgG were assessed in mice 7 days
prior to challenge for both experiments. Increased LPS-
specific IgG was observed in the glycoconjugate þ SAS
vaccinated group when compared with animals vaccinated
with LPS only ( p, 0.001). Although experiment 2 had
higher levels of antibody ( p, 0.01), we observed no evi-
dence for the pattern between vaccination groups differing
between experiments ( p. 0.05; figure 6). No significant
differences were observed between LPS-specific IgM levels
from the glycoconjugate and LPS vaccine groups (see the
electronic supplementary material, figure S5).
5. Discussion
Traditional glycoconjugate vaccine production using chemi-
cal conjugation requires that the glycan from the pathogenic
organism is isolated and detoxified by stripping components
such as lipid A, and that sufficient material is present to
be chemically linked to a protein. The procedures involve
harsh chemical treatments, can be extremely time consuming,
often produce low yields, and are relatively expensive.
In addition, the material generated at each step needs to be
verified for purity and variation between vaccine batches is
common. This process is also particularly difficult and hazar-
dous for F. tularensis subsp. tularensis and holarctica owing to
risks associated with aerosol generation and the low infec-
tious dose. In this study, we used recombinant technology
for the continuous generation of F. tularensis O-antigen
within a safe laboratory strain of E. coli (figure 1).
The F. tularensis subsp. tularensis and subsp. holarctica
repeating O-antigen subunit consists of a tetrasaccharide with
the structure 4-a-D-GalNAcAN-(1–4)-a-D-GalNAcAN-(1–3)-
b-D-QuiNAc-(1–2)-b-D-Qui4NFm-(1-), where GalNAcAN is
2-acetamido-2-deoxy-O-D-galact-uronamide, Qui4NFm is 4,6-
dideoxy-4-formamido-D-glucose and the reducing end group
QuiNAc is 2-acetamido-2,6-dideoxy-O-D-glucose [30]. Exploit-
ing the relaxed sugar substrate specificity of CjPglB and the
ability to target protein glycosylation, we generated a glycocon-
jugate vaccine by glycosylating ExoA from P. aeruginosa with
the F. tularensis O-antigen repeat unit. This glycoconjugate vac-
cine was purified to a typical yield of 3 mg ml21 of protein
from a 2 l starting culture of E. coli. Thus, we demonstrate
that the relaxed substrate specificity seen to be required by
CjPglB extends to the ability to transfer glycans containing
QuiNAc at their reducing ends.
PGCT has previously been used to produce a puri-
fied S. dysenteriae O-antigen/ExoA combination but the
vaccine potential of this conjugate has not been reported [15].
More recently Iwashkiw et al. [14] used PGCT to link a
Y. enterocolitica 09 polymer composed ofN-formyl perosamine
to a multidrug efflux pump component protein, AcrA, from
C. jejuni. The construct was shown to be a useful diagnostic
tool for Brucella abortus in bovine sera. The F. tularensis
O-antigen/ExoA glycoconjugate produced in this study is
the first report of a recombinantly generated glycoconjugate
to be protective in an infectious disease model.
Vaccination with the test glycoconjugate was shown to
provide protection against challenge with F. tularensis subsp.
holarctica strain HN63, providing both an increased time to
death compared with vaccination with LPS alone and signifi-
cantly reduced bacterial loads (figures 4 and 5). The mice also
had reduced inflammatory cytokine levels (see the electronic
supplementarymaterial, figure S4), correlatingwith the reduced
bacterial load. This is indicative of an appropriate early host
immune response to counteract the pathogen. Importantly,
mice vaccinated with the glycoconjugate showed an altered
immunological response compared with mice vaccinated with
LPS alone. While the immune response against LPS is primarily
a humoral immune response characterized by a dominance of
IgM rather than IgG antibodies, the glycoconjugateþ SAS
vaccinated mice showed a large increase in the production
of IgG (figure 6). Although increased IgG antibody level cannot
be taken to mean direct evidence of a shift to a T-cell-dependent
response, our results tentatively represent a proof of principle for
the use of glycoconjugate vaccines againstF. tularensisbydemon-
strating the expected shift in immune response from humoral to
cell-mediatedwhen the LPSO-antigen is conjugated to a protein
and administered with an appropriate adjuvant.
The Sigma Adjuvant System was selected for use in this
study because monophosphoryl lipid A (MPL)-based adju-
vants have been demonstrated to be safe and efficacious
immunostimulants in a number of vaccines including Cervarix
(GlaxoSmithKline Ltd) [34]. The human papillomavirus vac-
cine Cervarix is licensed with an adjuvant combination of
MPL and aluminium hydroxide. Furthermore, previous studies
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Figure 6. Increased IgG response in glycoconjugate vaccinated mice 7 days
prior to challenge. Increased LPS-specific IgG was observed in the
glycoconjugate þ SAS vaccinated group when compared with mice
vaccinated with LPS only ( p, 0.001).
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have shown that SAS is a suitable adjuvant for polysaccharide
vaccine candidates for other intracellular pathogens [35].
Currently, the LVS-attenuated strain is the gold standard
vaccine for F. tularensis. However, there are significant safety
concerns before this vaccine can be licensed for use in
humans. Sebastain et al. [36] attempted to incorporate the
immunogenic components of the F. tularensis LVS vaccine
whilst removing the adverse effects of the vaccine by combining
an O-antigen–tetanus toxoid chemical conjugate with a highly
attenuated F. tularensis LVS mutant that is unable to generate
O-antigen. Unfortunately, while this vaccine improved the
safety of the live vaccine, it conferred only partial protection
in mice against intranasal challenge with wild-type strain
SchuS4 [36]. Recently, Kim et al. [37] demonstrated that the
F. tularensis LVS strain can be further attenuated by removing
O-antigen polymerase function (Wzy) leading to a bacterium
that is coated with a single repeat unit. This strain was capable
of inducing high-level protection against type B F. tularensis in
Balb/C mice following intranasal infection, but it did not
match the LVS strain in terms of protection against type A
F. tularensis challenge. However, the study demonstrates the
importance of the O-antigen as an inducer of immunological
response and the necessity to include this component in the vac-
cine, implying the necessity for a vaccine that induces both
cellular and humoral immunity [37], such as a glycoconjugate.
The results from the present study represent a significant
advance in the application of bacterial PGCT to produce
successful glycoconjugate vaccines. The versatility and
recombinant nature of this system will facilitate vaccine
design. For example, additional glycosylation sites can be
engineered into ExoA to improve the ratio of glycan to
protein in the glycoconjugate. In these studies 10 mg of puri-
fied LPS were compared with 10 mg of total glycoconjugate
measured by bicinchonic acid assay, an assay that detects
only the concentration of protein and not of glycan. The
mice vaccinated with glycoconjugate will have received sub-
stantially lower doses of O-antigen than the mice vaccinated
with LPS. Increasing the amount of conjugated O-antigen
given to mice could substantially improve efficacy. In
addition our results demonstrate that both glycosylation
sequons grafted within ExoA are capable of being occupied
(see the electronic supplementary material, figure S2). The
abundance of glycan signal seen near the size where unglyco-
sylated ExoA normally migrates on an SDS PAGE gel shows
that a significant amount of glycoprotein carries single repeat
units. It is likely therefore that in this system, CjPglB com-
petes with the F. tularensis O-antigen polymerase (Wzy).
We are currently working on modulating the level of
CjPglB to ensure that higher polymer length glycans are
attached. An advantage of this technology over traditional
chemical conjugation methods is that the protein to be glyco-
sylated can easily be ‘swapped out’ and replaced with
another protein of choice. This step requires only two protein
modifications, consisting of a signal sequence to ensure it is
delivered to the periplasm and the addition of a ‘glycosyla-
tion tag’ sequon at the N- or C- terminus. This means that
several glycoconjugate combinations can be rapidly pro-
duced and purified and combined to provide multiple
immunogenic epitopes within the vaccine. This is particularly
significant as the intracellular pathogen F. tularensis has been
notoriously difficult in deriving candidate antigens that
protect against infection.
We are currently working towards modifying a number of
immunogenic F. tularensis proteins to generate a dual-specific
immune response against both the glycan and the protein.
Future work will focus on using glycotags to optimize the effi-
cacy of recombinant F. tularensis glycoconjugate vaccines. This
study demonstrates the efficacy of a recombinant glycoconju-
gate vaccine produced by PGCT and provides a foundation
for a new era in the generation of glycoconjugate vaccines.
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